A Gallini1, A Yrondi, C Cantet, M Poncet, B Vellas, L Schmitt, S Andrieu. 1. Adeline Gallini, PharmD, PhD, Epidemiology Department 37 allées Jules Guesde, 31062 Toulouse Cedex, Tel : +33 5 61 14 56 81, Fax : + 33 5 62 26 42 40, Email : adeline.gallini@univ-tlse3.fr.
Abstract
Low docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) concentration has been associated with the development of some psychiatric disorders. OBJECTIVES: to assess the association between red blood cell (RBC) DHA-EPA concentration and psychotropic drug use in older adults and between the 1-year change in RBC DHA-EPA and psychotropic drug use at 12 months. DESIGN: secondary analysis of multicenter, randomized controlled trial testing multidomain intervention and/or n-3 PUFA supplement on cognitive function (MAPT study). SETTING: France, 2008-2014. PARTICIPANTS: 1680 participants ≥70 years, community-dwelling were included. MEASUREMENTS: Psychotropic drug use was self-reported during medical interviews and assessments. RBC n-3 PUFA concentration was defined by % of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) among total fatty acids. Logistic regressions models controlling for age, sex, education, depression risk and intervention group were used. RESULTS:1594 participants had baselineDHA-EPA concentration available (mean age=75.5±4.5 years, 65% females). At baseline, participants with DHA-EPA ≤4.82% (lowest quartile) reported higher prevalence of use of overall psychotropic drugs (34.0% vs 24.4%; aOR=1.33, 95%CI=[1.03-1.72]), anxiolytic/hypnotic drugs (25.0% vs 18.2%; aOR=1.42, 95%CI=[1.07-1.89]), and antidepressants (18.3% vs 13.5%; aOR=1.25, 95%CI=[0.93-1.72]) than participants with higher DHA-EPA. Participants who experienced an increase in DHA-EPA from baseline were less likely to use a psychotropic drug at 12 months than participants with no change or a decrease (aOR=0.72, 95%CI=[0.55-0.96]). CONCLUSION:Low RBC DHA-EPA concentration was independently associated with psychotropic drug use. Future studies are needed to assess whether low RBC DHA-EPA is a risk marker for psychotropic drug use in older adults and to better understand underlying pathophysiological mechanisms. Registration number: ClinicalTrials.gov database (NCT00672685).
RCT Entities:
Low docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) concentration has been associated with the development of some psychiatric disorders. OBJECTIVES: to assess the association between red blood cell (RBC) DHA-EPA concentration and psychotropic drug use in older adults and between the 1-year change in RBC DHA-EPA and psychotropic drug use at 12 months. DESIGN: secondary analysis of multicenter, randomized controlled trial testing multidomain intervention and/or n-3 PUFA supplement on cognitive function (MAPT study). SETTING: France, 2008-2014. PARTICIPANTS: 1680 participants ≥70 years, community-dwelling were included. MEASUREMENTS: Psychotropic drug use was self-reported during medical interviews and assessments. RBC n-3 PUFA concentration was defined by % of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) among total fatty acids. Logistic regressions models controlling for age, sex, education, depression risk and intervention group were used. RESULTS: 1594 participants had baseline DHA-EPA concentration available (mean age=75.5±4.5 years, 65% females). At baseline, participants with DHA-EPA ≤4.82% (lowest quartile) reported higher prevalence of use of overall psychotropic drugs (34.0% vs 24.4%; aOR=1.33, 95%CI=[1.03-1.72]), anxiolytic/hypnotic drugs (25.0% vs 18.2%; aOR=1.42, 95%CI=[1.07-1.89]), and antidepressants (18.3% vs 13.5%; aOR=1.25, 95%CI=[0.93-1.72]) than participants with higher DHA-EPA. Participants who experienced an increase in DHA-EPA from baseline were less likely to use a psychotropic drug at 12 months than participants with no change or a decrease (aOR=0.72, 95%CI=[0.55-0.96]). CONCLUSION: Low RBC DHA-EPA concentration was independently associated with psychotropic drug use. Future studies are needed to assess whether low RBC DHA-EPA is a risk marker for psychotropic drug use in older adults and to better understand underlying pathophysiological mechanisms. Registration number: ClinicalTrials.gov database (NCT00672685).
Entities:
Keywords:
elderly; omega-3 fatty acids; prevention; psychotropic drug use
Authors: Alan D Dangour; Peter J Whitehouse; Kevin Rafferty; Stephen A Mitchell; Lesley Smith; Sophie Hawkesworth; Bruno Vellas Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472
Authors: J Alonso; M C Angermeyer; S Bernert; R Bruffaerts; T S Brugha; H Bryson; G de Girolamo; R Graaf; K Demyttenaere; I Gasquet; J M Haro; S J Katz; R C Kessler; V Kovess; J P Lépine; J Ormel; G Polidori; L J Russo; G Vilagut; J Almansa; S Arbabzadeh-Bouchez; J Autonell; M Bernal; M A Buist-Bouwman; M Codony; A Domingo-Salvany; M Ferrer; S S Joo; M Martínez-Alonso; H Matschinger; F Mazzi; Z Morgan; P Morosini; C Palacín; B Romera; N Taub; W A M Vollebergh Journal: Acta Psychiatr Scand Suppl Date: 2004
Authors: Nicole L Cockayne; Shantel L Duffy; Rosalind Bonomally; Amelia English; Paul G Amminger; Andrew Mackinnon; Helen M Christensen; Sharon L Naismith; Ian B Hickie Journal: Trials Date: 2015-06-03 Impact factor: 2.279